Executive VP
New York, NY (USA)
Role(s):
C-Level Executive (CEO, CFO, etc.)
BSA
Find More Startups
Startup
Location:
New York
Industry:
Bio-Technology
Year Founded:
2015
Number Employees:
1-10 people
Business Stage:
Growth (not profitable)
Entity Type:
Limited Liability Company
Description:
Through an exclusive partnership with a leading consortium of scientists and doctors specializing in stem cell treatments for life threatening diseases, we will be developing stem cell clinics and wellness centers around the world to treat people with serious diseases, that up until now, have had no cure. Our scientists and doctors have deep affiliations with major medical universities around the world and have received hundreds of millions of dollars in research grants, endowments, and legislative appropriations for ongoing research. We currently have 9 diseases treated to a high degree and there are dozens of others with high success rates with more than 400 diseases researched on an ongoing basis.
Our company is planning to open several clinics within major organ transplant hospitals around the world, starting in South America, then Europe, Asia, and North America, and we will offer stem cell treatments to treat devastating diseases and illnesses, along with rejuvenation services to patients in our locations. We intend to capitalize on our co-location arrangements within the hospitals to exceed patient counts and profitability, and we will draw all of our experience from a major clinic that our medical partners have operated internationally over the past 4 years. We also plan to market our clinics in North America to serve the growing medical tourism industry and we will provide people the opportunity to obtain out patient stem cell treatments and enjoy a vacation at the same time.
We are raising capital through a "PPM" and seek individuals who see our vision and wish to leverage their capital to earn passive, substantial returns and make a real difference in the health of people everywhere. This is a passive income opportunity with a substantial fixed cash dividend payout including a share in the asset value of the company to be realized through several exit strategies.